Dr. Shannon E. Doyle, MD.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 230
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Medical College of Wisconsin
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MN license 37336 -
Nephrology Physician
MN license 39336
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Allina United Hospital Saint PAul, MN
- M Health Fairview St John's Hospital Maplewood, MN
- Hennepin County Medical Center Minneapolis, MN
- M Health Fairview Woodwinds Hospital Woodbury, MN
- St Croix Regional Medical Center Saint Croix Falls, WI
Medical groups
- Healtheast Medical Research Institute (649 clinicians)
- St. Croix Regional Medical Center (131 clinicians)
- Associated Nephrology Consultants PA (15 clinicians)
- Healtheast Woodwinds Hospital (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 5,716
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Dialysis services, 2-3 physician visits per month (20 years or older) | 192 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 184 | 67 |
| Home dialysis services per month (20 years or older) | 87 | 13 |
| Insertion of needle into vein for collection of blood sample | 68 | 38 |
| Established patient office or other outpatient visit, 30-39 minutes | 51 | 37 |
| Analysis of central arterial pressure with review by physician | 44 | 35 |
| Dialysis services, 1 physician visit per month (20 years or older) | 36 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 27 | 26 |
| Hemodialysis procedure with physician evaluation | 25 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $164 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $83.08 |
|---|---|
| Calliditas Therapeutics US Inc. | $25.57 |
| Travere Therapeutics, Inc. | $23.46 |
| Ardelyx, Inc. | $17.89 |
| Novo Nordisk Inc | $14.13 |
| Food and Beverage | $164 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $3,227,111 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Akebia Therapeutics Inc - A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Genzyme Corporation · Recruiting · NCT06500702 - A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Takeda Pharmaceuticals U.S.A., Inc. · Recruiting · NCT06963827 - A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.